Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AesRx LLC

Division of Baxter International Inc.
www.aesrx.com

Latest From AesRx LLC

Global Blood Therapeutics Inc.

Global Blood Therapeutic Inc.'s homegrown lead candidate is an oral, once-daily drug aimed at sickle cell disease, a genetic condition that causes red blood cells to become deformed or “sickled." The goal with GBT440 is to correct the disease, so that patients would actually have no evidence of it following treatment.

BioPharmaceutical

Deals Shaping The Medical Industry, September 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

BioPharmaceutical Medical Device

U.K Drug-Repurposing Program Expands, Attracts Industry Support

Britain moves ahead with a drug-repurposing research program that brings together big pharma and academic researchers in novel collaborations.

BioPharmaceutical United Kingdom

Patient Advocacy And PDUFA VI: Next Steps Could Include Involvement In Reviews, More Scientific Briefings for FDA Staff

Disease advocacy organizations are expanding their “honest broker” function in drug development into the early stages of the regulatory discussions. They are engaging in the patient-focused meetings established by PDUFA V and finding more ways to interact with FDA review staff on general development issues in their specific areas. That may become the model for building on the patient input process in the next user fee agreement.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Baxter International Inc.
  • Senior Management
  • Stephen R Seiler, CEO
    Warren C Stern, PhD, SVP, Drug Dev.
  • Contact Info
  • AesRx LLC
    Phone: (617) 965-2521
    275 Grove St.
    Ste. 2-400
    Newton, MA 02466
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register